Erez Vigodman - Teva Pharma CEO
TEVA Stock | USD 13.01 0.13 1.01% |
CEO
Mr. Erez Vigodman serves as President, Chief Executive Officer and Director at Teva Pharmaceutical Industries Limited since February 11, 2014 after joining Tevas Board of Directors in 2009. From 2010 to 2014, he served as President and Chief Executive Officer of Adama Agricultural Solutions Ltd. . From 2001 to 2009, he served as President and Chief Executive Officer of Strauss Group Ltd. Mr. Vigodman is a member of the Advisory Committee to the Israel National Economic Council and the International Advisory Board of the Israel Science Technology Innovation Policy Institute. Mr. Vigodman received a Bachelors degree in Accounting and Economics from Tel Aviv University in 1987 and is a graduate of the program of Management Development at Harvard Graduate School of Business Administration. Mr. Vigodman is a certified public accountant. since 2014.
Age | 55 |
Tenure | 10 years |
Address | 124 Dvora HaNevi?a Street, Tel Aviv, Israel, 6944020 |
Phone | 972 3 914 8213 |
Web | https://www.tevapharm.com |
Teva Pharma Management Efficiency
The company has return on total asset (ROA) of 0.0454 % which means that it generated a profit of $0.0454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0736) %, meaning that it created substantial loss on money invested by shareholders. Teva Pharma's management efficiency ratios could be used to measure how well Teva Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.03. In addition to that, Return On Capital Employed is expected to decline to 0.01. At present, Teva Pharma's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 914.4 M, whereas Total Assets are forecasted to decline to about 26.4 B.Similar Executives
Showing other executives | CEO Age | ||
Richard Nanula | Lucy Scientific Discovery | 63 | |
Paul Thomson | Aurora Cannabis | N/A | |
Kristin Peck | Zoetis Inc | 53 | |
James Hall | Lifecore Biomedical | 61 | |
Irwin Simon | Tilray Inc | 66 | |
Miguel Martin | Aurora Cannabis | 51 | |
Brendan Kennedy | Tilray Inc | 44 | |
Scott Smith | Viatris | 62 | |
Mark Zekulin | Canopy Growth Corp | N/A | |
Michael JD | Cronos Group | 37 | |
Jeffrey Simmons | Elanco Animal Health | 57 | |
Juan Alaix | Zoetis Inc | 67 | |
Christophe Weber | Takeda Pharmaceutical Co | 58 | |
David Klein | Canopy Growth Corp | 60 | |
Neil Swift | Takeda Pharmaceutical Co | N/A | |
Terry Booth | Aurora Cannabis | 54 |
Management Performance
Return On Equity | -0.0736 | ||||
Return On Asset | 0.0454 |
Teva Pharma Industries Leadership Team
Elected by the shareholders, the Teva Pharma's board of directors comprises two types of representatives: Teva Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharma's management team and ensure that shareholders' interests are well served. Teva Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Moshe Many, Independent Director | ||
Richard Daniell, Executive Vice President - European Commercial | ||
Mark Sabag, Executive Vice President, Chief Human Resources Officer and Global Communications and Brand | ||
Ronit SatchiFainaro, Independent Director | ||
Richard Lerner, Independent Director | ||
Galia Maor, Independent Director | ||
Janet Vergis, Independent Director | ||
Carlo Notaristefani, CEO of Global Operations and President of Global Operations | ||
Richard Francis, CEO President | ||
JeanMichel Halfon, Statutory - independent director | ||
Eli Shani, Executive Vice President - Global Marketing and Portfolio | ||
Dipankar Bhattacharjee, Senior Vice President CFO Americas and Head of Finance Operations | ||
Abbas Hussain, Independent Director | ||
Yitzhak Peterburg, Director | ||
Hafrun Fridriksdottir, Executive Vice President and Presidentident of Global Generics R&D | ||
Ran Meir, Head Relations | ||
Perry Nisen, Independent Director | ||
Isaac Abravanel, Group Executive Vice President Teva Corporate in Israel and Global Community Alliances, Director | ||
David Stark, Executive Vice President, Chief Legal Officer | ||
Tal Zaks, Independent Director | ||
Amir Elstein, Vice Chairman of the Board | ||
Dan Suesskind, Director | ||
Arie Belldegrun, Independent Director | ||
Richard Egosi, Chief Legal Officer and Group Executive VP | ||
Andrew Weil, Chief Accounting Officer | ||
Jean Halfon, Statutory - independent director | ||
Sven Dethlefs, Executive Vice President - Global Marketing & Portfolio and International Markets Commercial | ||
Robert Koremans, President CEO-Global Specialty Medicines | ||
Dov Bergwerk, Acting Secretary | ||
Gerald Lieberman, Independent Director | ||
Roberto Mignone, Independent Director | ||
Rosemary Crane, Independent Director | ||
Nechemia Peres, Independent Director | ||
Roger Abravanel, Independent Director | ||
Eyal Desheh, CFO and Group Executive VP | ||
Gianfranco Nazzi, Executive Vice President - International Markets Commercial | ||
Kare Schultz, CEO Pres | ||
Iris BeckCodner, Group Executive Vice President - Corporate Marketing Excellence and Communication | ||
Amir Weiss, Senior Vice President Chief Accounting Officer | ||
Brendan OGrady, Executive Vice President - North America Commercial | ||
Michael Hayden, President - Global Research and Development, Chief Scientific Officer | ||
Gabrielle Sulzberger, Statutory Independent Director | ||
Galia Inbar, Executive Vice President - Global Communications, Brand and ESG, Chief Human Resource Officer | ||
Eric Drape, Executive Vice President - Global Operations | ||
Vikki Conway, Acting Resources | ||
Erez Vigodman, CEO and President Director and Member of Fin. and Invesment Committee | ||
Eliyahu Kalif, Chief Financial Officer, Executive Vice President | ||
Kathleen Veit, Global President | ||
Joseph Nitzani, Independent Director | ||
Timothy Wright, Head - Business Development, Strategy and Innovation | ||
Sigurdur Olafsson, CEO of Global Generic Medicines Group and President of Global Generic Medicines Group | ||
Murray Goldberg, Independent Director | ||
Dan Propper, Independent Director | ||
Ory Slonim, Independent Director | ||
Michael McClellan, CFO, Executive Vice President | ||
Kevin Mannix, Head of Global Investor Relations and VP | ||
Kaare Schultz, President, Chief Executive Officer, Director | ||
Sol Barer, Independent Chairman of the Board |
Teva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.0736 | ||||
Return On Asset | 0.0454 | ||||
Profit Margin | (0.04) % | ||||
Operating Margin | 0.28 % | ||||
Current Valuation | 32.25 B | ||||
Shares Outstanding | 1.13 B | ||||
Shares Owned By Institutions | 52.65 % | ||||
Number Of Shares Shorted | 11.56 M | ||||
Price To Earning | 15.67 X | ||||
Price To Book | 1.99 X |
Teva Pharma Investors Sentiment
The influence of Teva Pharma's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Teva. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Teva Pharma's public news can be used to forecast risks associated with an investment in Teva. The trend in average sentiment can be used to explain how an investor holding Teva can time the market purely based on public headlines and social activities around Teva Pharma Industries. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Teva Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Teva Pharma's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Teva Pharma's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Teva Pharma.
Teva Pharma Implied Volatility | 71.86 |
Teva Pharma's implied volatility exposes the market's sentiment of Teva Pharma Industries stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Teva Pharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Teva Pharma stock will not fluctuate a lot when Teva Pharma's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Teva Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Teva Pharma's short interest history, or implied volatility extrapolated from Teva Pharma options trading.
Currently Active Assets on Macroaxis
When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Teva Stock analysis
When running Teva Pharma's price analysis, check to measure Teva Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharma is operating at the current time. Most of Teva Pharma's value examination focuses on studying past and present price action to predict the probability of Teva Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharma's price. Additionally, you may evaluate how the addition of Teva Pharma to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Transaction History View history of all your transactions and understand their impact on performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Teva Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (0.50) | Revenue Per Share 14.161 | Quarterly Revenue Growth 0.148 | Return On Assets 0.0454 |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.